INDEPENDENT ANTI-DOPING REFERENCE2026 · CHECKED 08 NOV 2027 PUBLISHED ↗
WADAFUK!?
Source-checked educational research

11β-Methyl-19-nortestosterone.

S1
Source-checked educational research

Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.

REGULATORY SUMMARY2026 LIST

Prohibited at all times

11β-Methyl-19-nortestosterone is covered by S1.1 of the effective 2026 WADA List and is prohibited in and out of competition. S1.1 applies to exogenous administration; its coverage is not limited to the named examples and includes relevant esters. [3]

S1.1; 2026 List, printed pages 5–6 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.

EVIDENCE / 01

Human contraceptive research

A randomized 28-day trial in 42 healthy men studied the dodecylcarbonate prodrug of 11-beta-methyl-19-nortestosterone. It reported suppression of gonadotropins and sex hormones, with lipid, weight and hematologic changes and some sexual-function complaints. [1]

Limits of this evidence
  • The prodrug trial is distinct from evidence for every form of the named parent. It does not demonstrate long-term contraceptive efficacy or safety.
EVIDENCE / 02

List year

The 2026 List is the effective edition on this review date. The checked 2027 S1 text showed no change, but the 2027 edition does not take effect until 1 January 2027. [3] [4] [2]

Limits of this evidence
  • Consult the official edition and responsible anti-doping organization for consequential decisions. This reference does not provide medical advice, a TUE decision, product certification or individual clearance.

What remains uncertain

  • This is a targeted source check, not a systematic review or independent clinical/regulatory sign-off. Uncited draft claims remain unpublished.
  • Chemical registry identifiers, every alias and jurisdiction-specific product availability have not been exhaustively reconciled.
TRACEABILITY

Check the sources.

These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.

  1. Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men. ↗Accessed 2026-11-10 · indexed original abstract read via Europe PMC MED record; full article not reviewed

    Abstract; PMID 31976519

  2. 2027 Prohibited List resource page ↗Accessed 2026-11-10 · relevant primary-source text read · FUTURE 2027 SOURCE

    Resource description and effective date

  3. WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant primary-source text read

    Introduction and S1, printed pages 3, 5–6

  4. WADA 2027 Prohibited List, currently linked English file ↗Accessed 2026-11-10 · relevant primary-source text read · FUTURE 2027 SOURCE

    Cover and S1, printed pages 1, 5–6

Before acting on this information

Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.

Something wrong? Prepare a correction draft ↗